RIO DE JANEIRO, BRAZIL - Pfizer has announced that it has begun testing the safety in humans of a new pill against the coronavirus that could be used at the first symptoms of illness.
If proven successful in trials, the pill could be prescribed early in an infection to block viral multiplication before the patient's condition worsens. The drug binds to an enzyme called protease to prevent the virus from replicating. Protease inhibitor drugs have had success in treating other types of viruses, including HIV and hepatitis C.
"Considering the mutated form of SARS-CoV-2 and the ongoing global . . .